By Bhanvi Satija

LONDON (Reuters) -Metsera has become the obesity drug market’s hottest ticket.

The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to its pipeline of experimental treatments as competition intensifies in the booming $150 billion weight-loss drug market.

Metsera’s lead candidate, MET-097i, is a once-monthly GLP-1 injectable.

Unlike Novo’s Wegovy and Eli Lilly’s Zepbound, which are both weekly shots, it works by selectively binding to a protein pathway linked to weight loss and insulin release, potentially reducing side effects and dosing frequency.

PROMISING CANDIDATES IN THE PIPELINE

Last month, data from a mid-stage study showed the highest dose of the drug helped patients lose an average of up to 14.1%

See Full Page